We are live on
!
Find out more
CS
Candriam SCA Portfolio holdings
AUM
$19.3B
1-Year Est. Return
39.18%
This Fund
S&P 500
This Quarter
Est. Return
+8.76%
1 Year Est. Return
+39.18%
3 Year Est. Return
+109.85%
5 Year Est. Return
+149.31%
10 Year Est. Return
+617.16%
AUM
$13.8B
AUM Growth
-$581M
(-4%)
Cap. Flow
-$2.79B
Cap. Flow
% of AUM
-20.16%
Top 10 Holdings %
Top 10 Hldgs %
25.18%
Holding
905
New
29
Increased
148
Reduced
448
Closed
194
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Lam Research
LRCX
|
+$66.4M |
| 2 |
Valero Energy
VLO
|
+$28.9M |
| 3 |
SLB Ltd
SLB
|
+$24.8M |
| 4 |
BNY
Bank of New York Mellon
BNY
|
+$22.6M |
| 5 |
PepsiCo
PEP
|
+$20.4M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$182M |
| 2 |
Apple
AAPL
|
+$148M |
| 3 |
Alphabet (Google) Class A
GOOGL
|
+$90.9M |
| 4 |
Amgen
AMGN
|
+$72.1M |
| 5 |
Tesla
TSLA
|
+$66.1M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 31.26% |
| 2 | Technology | 28.78% |
| 3 | Financials | 8.15% |
| 4 | Consumer Discretionary | 7.54% |
| 5 | Industrials | 7.28% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
201
Quest Diagnostics
DGX
$25.1B
| $14.3M | 0.1% |
101,803
-34,666
| -25% | -$4.78M |
|
202
Penumbra
PEN
$12.5B
| $14.3M | 0.1% |
41,568
+35,312
| +564% | +$10.8M |
|
203
Intuit
INTU
$81.1B
| $14.2M | 0.1% |
31,096
-13,029
| -30% | -$5.71M |
|
204
Replimune Group
REPL
$814M
| $14.2M | 0.1% |
612,193
-50,729
| -8% | -$991K |
|
205
Electronic Arts
EA
$52.4B
| $14.1M | 0.1% |
108,691
-92,558
| -46% | -$11.7M |
|
206
Clean Harbors
CLH
$16.1B
| $14M | 0.1% |
85,117
-15,734
| -16% | -$2.3M |
|
207
Fortinet
FTNT
$112B
| $14M | 0.1% |
184,590
-41,439
| -18% | -$2.82M |
|
208
Cardinal Health
CAH
$53.4B
| $13.8M | 0.1% |
146,390
-71,807
| -33% | -$6.07M |
|
209
Walmart Inc
WMT
$871B
| $13.4M | 0.1% |
255,246
-552
| -0.2% | -$27.8K |
|
210
Dover
DOV
$27.2B
| $13.3M | 0.1% |
89,887
-5,708
| -6% | -$816K |
|
211
Ascendis Pharma A/S
ASND
$16.7B
| $13.2M | 0.1% |
148,375
-102,000
| -41% | -$8.88M |
|
212
Crown Holdings
CCK
$12.8B
| $13.2M | 0.1% |
151,859
+8,036
| +6% | +$662K |
|
213
Halozyme
HALO
$9.72B
| $13.1M | 0.09% |
362,143
-35,807
| -9% | -$1.22M |
|
214
Mid-America Apartment Communities
MAA
$15.6B
| $13M | 0.09% |
85,571
-18,998
| -18% | -$2.85M |
|
215
Intercontinental Exchange
ICE
$82.4B
| $12.8M | 0.09% |
113,061
-294,144
| -72% | -$31.9M |
|
|
ACLX
216
DELISTED
Arcellx
ACLX
| $12.6M | 0.09% |
398,020
-49,134
| -11% | -$1.88M |
|
|
ISEE
217
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $12.4M | 0.09% |
315,832
-615,098
| -66% | -$21.7M |
|
218
Hannon Armstrong Sustainable Infrastructure Capital
HASI
$4.9B
| $12.3M | 0.09% |
491,291
-58,326
| -11% | -$1.53M |
|
219
Relay Therapeutics
RLAY
$4.02B
| $12.2M | 0.09% |
971,070
-267,802
| -22% | -$3.33M |
|
220
Iovance Biotherapeutics
IOVA
$2.23B
| $12.2M | 0.09% |
1,727,816
+33,896
| +2% | +$243K |
|
221
PTC Therapeutics
PTCT
$6.37B
| $11.9M | 0.09% |
291,652
+14,000
| +5% | +$685K |
|
|
NUVL
222
DELISTED
Nuvalent
NUVL
| $11.8M | 0.09% |
280,016
-43,835
| -14% | -$1.66M |
|
223
Newmont
NEM
$98.2B
| $11.7M | 0.08% |
56,888
-11,026
| -16% | -$500K |
|
224
Power Integrations
POWI
$3.54B
| $11.6M | 0.08% |
123,031
-72,764
| -37% | -$6.08M |
|
225
GE Aerospace
GE
$367B
| $11.6M | 0.08% |
132,772
-3,155
| -2% | -$255K |
|
Similar funds
PCM
A
MGP
LF
SOMRS
BPA
MIM
Candriam SCA's Q2 2023 Portfolio in Review
As of Q2 2023, Candriam SCA held 905 positions worth $13.8B, down 4% from $14.4B the previous quarter. Its ten largest holdings account for 25% of the portfolio.
Candriam SCA withdrew a net $2.79B in Q2 2023, closing 194 positions and reducing 448 holdings. Its most notable exit was Thomson Reuters, an estimated $19.8M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 31% of assets, up from 31% a quarter earlier, followed by Technology and Financials.
Against the trend, Candriam SCA opened a new position in Vir Biotechnology worth $8.7M.
- Candriam SCA's largest Q2 2023 buy was Vir Biotechnology: 354,645 shares worth $8.7M.
- Candriam SCA added most to Lam Research in Q2 2023, an estimated $66.4M increase.
- Candriam SCA's biggest Q2 2023 reduction was Microsoft, cutting an estimated $182M.
- Candriam SCA fully exited Thomson Reuters in Q2 2023, selling an estimated $19.8M.
- Candriam SCA's ten largest holdings make up 25% of its $13.8B portfolio in Q2 2023.
- Candriam SCA opened 29 new positions and closed 194 in Q2 2023.
- Candriam SCA's portfolio value fell 4% quarter-over-quarter to $13.8B.
Based on Candriam SCA's 13F filing for Q2 2023, filed 8 Aug 2023.